Harmony Biosciences Holdings (HRMY) Deferred Taxes (2022 - 2026)

Harmony Biosciences Holdings has disclosed Deferred Taxes across 5 years of filings, most recently posting -$3.9 million for Q1 2026.

• Deferred Taxes for Q1 2026 came in at -$3.9 million, up 10.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.9 million (up 77.26% YoY), and the FY2025 annual result was -$7.3 million, up 75.08% from the prior year.
• Deferred Taxes came in at -$3.9 million for Q1 2026 at Harmony Biosciences Holdings, down from $7.4 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $7.4 million in Q4 2025 to a low of -$14.3 million in Q2 2024.
• The 5-year median for Deferred Taxes is -$4.2 million (2022), against an average of -$4.2 million.
• Across the five-year window, Deferred Taxes tumbled 697.68% in 2024 and soared 209.89% in 2025, its largest moves.
• Harmony Biosciences Holdings' Deferred Taxes stood at -$4.3 million in 2022, then soared by 126.34% to $1.1 million in 2023, then sank by 697.68% to -$6.7 million in 2024, then jumped by 209.89% to $7.4 million in 2025, then slumped by 152.37% to -$3.9 million in 2026.
• The last three Deferred Taxes figures came in at -$3.9 million (Q1 2026), $7.4 million (Q4 2025), and -$3.9 million (Q3 2025), per Business Quant data.